ARDELYX, INC. — Director's Dealing 2016

Mar 8, 2016

SEC Form 4/A — Form 4/A

Issuer: ARDELYX, INC. (ARDX)
CIK: 0001437402
Period of Report: 2015-09-21

Reporting Person: Rosenbaum David P. (SVP, Drug Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-09-21	Common Stock	S	800	$22.0925	Disposed	22540	Direct
2015-09-22	Common Stock	S	600	$22.00	Disposed	21940	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	77592	Indirect

Footnotes

F1: This Amendment is filed to correct the account under which the Reporting Person sold the shares. The original filing reported a sale from the Reporting Person's trust whereas the transaction was executed using shares held in his individual account. All other information, including sale price and number of shares sold, was correct as originally reported.

F2: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 18, 2015.

F3: This transaction was executed in multiple trades in prices ranging from $22.00 to $22.37, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4: The shares are directly held by David Paul Rosenbaum and Susan Edelstein Rosenbaum, Trustees of the David Paul Rosenbaum Family Trust.